FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589798791> ?p ?o ?g. }

• W2589798791 endingPage "428" @default.
• W2589798791 startingPage "423" @default.
• W2589798791 abstract "Background: Ipilimumab is a fully human immunoglobulin G1 monoclonal antibody that increases antitumor T-cell responses. We conducted a meta-analysis of randomized controlled trials (RCTs) to evaluate the risk of FAEs associated with ipilimumab.Methods: We searched PubMed, EMBASE, and ASCO meeting abstract up to September 2016 for RCT comparing ipilimumab with no ipilimumab on cancer patients. Incidence rates, relative risk ratios (RRs), and 95% confidence intervals (CIs) were calculated using fixed- or random effects models. The primary end point was the association of ipilimumab with FAEs. Subgroup analyses were performed according to tumor type, concurrent therapy, and dose of ipilimumab.Results: A total of 5,466 patients from 10 RCTs were included. For patients receiving ipilimumab, the overall incidences of FAEs was 0.99% (95% CI: 0.48%-1.69%). Allocation to ipilimumab therapy increased the risk of FAEs (RR = 2.16, 95% CI, 1.03–4.54) significantly. Subgroup analyses reached statistical significance for prostate cancer, high dose of ipilimumab, and placebo as a control group. No evidence of publication bias was observed.Conclusions: Compared with control or placebo, ipilimumab was associated with an increased risk of FAEs in cancer patients. As ipilimumab gains greater clinical use, practitioners must be aware of the risks associated with its use." @default.
• W2589798791 created "2017-03-03" @default.
• W2589798791 creator A5025125524 @default.
• W2589798791 creator A5027767246 @default.
• W2589798791 creator A5039783554 @default.
• W2589798791 creator A5050268277 @default.
• W2589798791 creator A5056940726 @default.
• W2589798791 creator A5059561550 @default.
• W2589798791 creator A5066785128 @default.
• W2589798791 creator A5068628266 @default.
• W2589798791 creator A5079638418 @default.
• W2589798791 creator A5079883312 @default.
• W2589798791 creator A5086953111 @default.
• W2589798791 date "2017-02-24" @default.
• W2589798791 modified "2023-09-23" @default.
• W2589798791 title "Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab" @default.
• W2589798791 cites W1556990476 @default.
• W2589798791 cites W1598602811 @default.
• W2589798791 cites W1791759367 @default.
• W2589798791 cites W1826925790 @default.
• W2589798791 cites W1914776013 @default.
• W2589798791 cites W1979811833 @default.
• W2589798791 cites W1986215651 @default.
• W2589798791 cites W2022073464 @default.
• W2589798791 cites W2040190056 @default.
• W2589798791 cites W2097995306 @default.
• W2589798791 cites W2098414192 @default.
• W2589798791 cites W2122352969 @default.
• W2589798791 cites W2123363005 @default.
• W2589798791 cites W2124606227 @default.
• W2589798791 cites W2131754429 @default.
• W2589798791 cites W2139927762 @default.
• W2589798791 cites W2155599713 @default.
• W2589798791 cites W2156098321 @default.
• W2589798791 cites W2166662937 @default.
• W2589798791 cites W2418354692 @default.
• W2589798791 cites W2473218705 @default.
• W2589798791 cites W2480201404 @default.
• W2589798791 cites W2529373149 @default.
• W2589798791 cites W2531934133 @default.
• W2589798791 cites W2581935274 @default.
• W2589798791 cites W2991792334 @default.
• W2589798791 doi "https://doi.org/10.1080/14740338.2017.1297420" @default.
• W2589798791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28276859" @default.
• W2589798791 hasPublicationYear "2017" @default.
• W2589798791 type Work @default.
• W2589798791 sameAs 2589798791 @default.
• W2589798791 citedByCount "8" @default.
• W2589798791 countsByYear W25897987912017 @default.
• W2589798791 countsByYear W25897987912018 @default.
• W2589798791 countsByYear W25897987912019 @default.
• W2589798791 countsByYear W25897987912020 @default.
• W2589798791 countsByYear W25897987912021 @default.
• W2589798791 countsByYear W25897987912023 @default.
• W2589798791 crossrefType "journal-article" @default.
• W2589798791 hasAuthorship W2589798791A5025125524 @default.
• W2589798791 hasAuthorship W2589798791A5027767246 @default.
• W2589798791 hasAuthorship W2589798791A5039783554 @default.
• W2589798791 hasAuthorship W2589798791A5050268277 @default.
• W2589798791 hasAuthorship W2589798791A5056940726 @default.
• W2589798791 hasAuthorship W2589798791A5059561550 @default.
• W2589798791 hasAuthorship W2589798791A5066785128 @default.
• W2589798791 hasAuthorship W2589798791A5068628266 @default.
• W2589798791 hasAuthorship W2589798791A5079638418 @default.
• W2589798791 hasAuthorship W2589798791A5079883312 @default.
• W2589798791 hasAuthorship W2589798791A5086953111 @default.
• W2589798791 hasConcept C120665830 @default.
• W2589798791 hasConcept C121332964 @default.
• W2589798791 hasConcept C121608353 @default.
• W2589798791 hasConcept C126322002 @default.
• W2589798791 hasConcept C142724271 @default.
• W2589798791 hasConcept C143998085 @default.
• W2589798791 hasConcept C168563851 @default.
• W2589798791 hasConcept C187960798 @default.
• W2589798791 hasConcept C197934379 @default.
• W2589798791 hasConcept C203092338 @default.
• W2589798791 hasConcept C204787440 @default.
• W2589798791 hasConcept C27081682 @default.
• W2589798791 hasConcept C2777701055 @default.
• W2589798791 hasConcept C2781433595 @default.
• W2589798791 hasConcept C44249647 @default.
• W2589798791 hasConcept C535046627 @default.
• W2589798791 hasConcept C61511704 @default.
• W2589798791 hasConcept C71924100 @default.
• W2589798791 hasConcept C82789193 @default.
• W2589798791 hasConcept C95190672 @default.
• W2589798791 hasConceptScore W2589798791C120665830 @default.
• W2589798791 hasConceptScore W2589798791C121332964 @default.
• W2589798791 hasConceptScore W2589798791C121608353 @default.
• W2589798791 hasConceptScore W2589798791C126322002 @default.
• W2589798791 hasConceptScore W2589798791C142724271 @default.
• W2589798791 hasConceptScore W2589798791C143998085 @default.
• W2589798791 hasConceptScore W2589798791C168563851 @default.
• W2589798791 hasConceptScore W2589798791C187960798 @default.
• W2589798791 hasConceptScore W2589798791C197934379 @default.
• W2589798791 hasConceptScore W2589798791C203092338 @default.
• W2589798791 hasConceptScore W2589798791C204787440 @default.
• W2589798791 hasConceptScore W2589798791C27081682 @default.

• next